Do you want to read an article? Please log in or register.
STRATUS, a Phase II Study of Abituzumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease
Systemic Sclerosis
Related content
EULAR ® 2019
Systemic Sclerosis-Associated Interstitial Lung Disease
Distler et al. 2019. Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: Data from the SENSCIS trial. Oral presentation presented at: EULAR 2019 Congress; 12–15 June 2019; Madrid, Spain.
Systemic Sclerosis
Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study
Rheumatology (Oxford)
Li Q, Wallace L, Patnaik P, Alves M, Gahlemann M, Kohlbrenner V, Raabe C, Wang JR, Garry EM
doi: 10.1093/rheumatology/keaa547
Further Publications Rheumatology
Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression
Respirology
Stock CJW, Hoyles RK, Daccord C, Kokosi M, Visca D, De Lauretis A, Alfieri V, Kouranos V, Margaritopoulos G, George PM, Molyneaux PL, Chua F, Maher TM, Abraham DJ, Ong V, Donovan J, Sestini P, Denton CP, Wells AU, Renzoni EA
doi: 10.1111/resp.13988
Systemic SclerosisFurther Publications Rheumatology
Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process
Semin Arthritis Rheum
Roofeh D, Barratt SL, Wells AU, Kawano-Dourado L, Tashkin D, Strand V, Seibold J, Proudman S, Brown KK, Dellaripa PF, Doyle T, Leonard T, Matteson EL, Oddis CV, Solomon JJ, Sparks JA, Vassallo R, Maxwell L, Beaton D, Christensen R, Townsend W, Khanna D
doi: 10.1016/j.semarthrit.2021.08.001
Systemic Sclerosis
Hemodynamic response to treatment and outcome in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis
Arthritis Rheumatol.
Chauvelot L, Gamondes D, Berthiller J, Nieves A, Renard S, Catella-Chatron J, Ahmad K, Bertoletti L, Camara B, Gomez E, Launay D, Montani D, Mornex JF, Prévot G, Sanchez O, Schott AM, Subtil F, Traclet J, Turquier S, Zeghmar S, Habib G, Reynaud-Gaubert M, Humbert M, Cottin V
doi: 10.1002/art.41512.
RECOMMENDED
Systemic Sclerosis
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Ann Rheum Dis
Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O, SENSCIS trial investigators.
doi: 10.1136/annrheumdis-2020-217331
Systemic Sclerosis
Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease
Ann Rheum Dis.
Valenzi E, Bulik M, Tabib T, Morse C, Sembrat J, Trejo Bittar H, Rojas M, Lafyatis R
doi: 10.1136/annrheumdis-2018-214865.
Systemic Sclerosis
Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature
Rheumatology (Oxford).
Bonhomme O, André B, Gester F, de Seny D, Moermans C, Struman I, Louis R, Malaise M, Guiot J
doi: 10.1093/rheumatology/
Further Publications Rheumatology
Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of the SENSCIS trial
Arthritis Rheumatol
Maher TM, Mayes MD, Kreuter M, Volkmann ER, Aringer M, Castellvi I, Cutolo M, Stock C, Schoof N, Alves M, Raghu G, SENSCIS trial investigators.
doi: 10.1002/art.41576